Eltrombopag

A Phase II Study of Eltrombopag as a Novel Therapeutic Approach for Patients With Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) With TET2 Mutations

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 2
Enrollment
25 patients (estimated)
Sponsors
Case Comprehensive Cancer Center
Tags
Thrombopoietin Receptor Agonist (TPO-RA), White Blood Cell Stimulant
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2016
NCT Identifier
NCT06630221

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.